Health Alert:

See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.

Penn Neuro-Oncology Symposium Brain Tumors 2018

Master Class in Brain Tumor Treatment - Best Practices

Brain Tumors 2018 Event Graphic
Friday, June 8, 2018
7:00 AM - 3:15 PM

Perelman Center for Advanced Medicine
Law Auditorium | Jordan Medical Education Center 
3400 Civic Center Boulevard
Philadelphia PA 19104

The Penn Brain Tumor Center, Abramson Cancer Center

The purpose of this educational activity is to provide a review of new treatment options in neuro-oncology, including surgical techniques and intraoperative imaging that have improved patient outcomes. Sessions will feature the latest advances in state-of-the-art care for practicing clinicians treating patients with brain tumors. Cutting-edge topics in precision medicine, including genetic, translational, and clinical research will also be featured. Each section will conclude with an audience interactive panel discussion with question and answer session.

Target Audience

This symposium is designed for neurosurgeons, neuro-oncologists, neurologists, radiologists, medical oncologists, radiation oncologists, primary care physicians, oncology nurses, and other healthcare professionals involved in the treatment of patients with brain tumors. Additionally, patients and their caregivers, family members, advocates and members of the public who may benefit from understanding current innovative approaches to brain tumor care are invited.

Learning Objectives

Upon completion of this course, participants should be able to:

  • Review the new WHO classification of brain tumors and how molecular profiling affects diagnosis, MRI interpretation, prognosis and therapy of patients with gliomas
  • Describe advances in the surgical treatment of brain tumors including the use of fiber tracking (DTI), awake craniotomy, brain mapping, laser thermocoagulation, and fluorescence IGS (image-guided surgery)
  • Explain the role of immune system to defend against CNS malignancy including the new class of checkpoint inhibitors and the potential use of CAR-T cell therapy
  • Review the benefits and application of proton therapy for low-grade and malignant gliomas
  • Describe the scientific rationale, practical application, and survival benefit of electric field therapy for malignant brain tumors
  • Explain the rationale and potential for viral therapies for malignant gliomas
  • Understand keys to survivorship: The patient’s journey – From the eyes and voices of actual patient heroes
  • Describe recent advances in anti-angiogenic therapy in the treatment of gliomas
At the completion of this course patients and families will be able to: 
  • Describe the latest advances in brain cancer treatment 
  • Demonstrate familiarity with the terminology and technical aspects of brain cancer care Demonstrate patient-active behavior in working with the healthcare team to make ongoing treatment decisions


In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Of Credit

  • PHYSICIANS:  Penn Medicine designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • NURSES: The program will award 6.25 contact hours.
  • PHYSICIAN ASSISTANTS: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of
    6.25 Category 1 credits for completing this activity.


Penn Medicine, Office of Continuing Medical and Interprofessional Education, adheres to the ACCME Standards for Commercial Support. Faculty and planner’s disclosure information will be made available in the conference materials and syllabus. Faculty members are also expected to disclose to participants any discussion of off-label and / or investigational use of pharmaceutical products or devices within their presentations.


Registration in now closed. Walk-in are welcomed.

Event Link:
View Invitation